drug · small molecule
elafibranor
Marketedupdated 6mo agoby Ipsen SA🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cholangitis and biliary liver cirrhosis and 7 investigational indications.
targets
Peroxisome proliferator-activated receptor alphaPeroxisome proliferator-activated receptor delta
all catalysts(0)
nothing on the calendar yet
Trials studying elafibranor
- —A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
- —Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
- phase3A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- phase3Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
- phase3A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- phase3A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
- phase2A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
- phase3A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 10, 2029
~2.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Mar 30, 2037method-of-use (U-3955)US 11185519
- Mar 30, 2037method-of-use (U-1854)US 11331292
- Mar 30, 2037method-of-use (U-1854)US 11850223
- Mar 30, 2037method-of-use (U-3955)US 11857523
- Mar 30, 2037method-of-use (U-1854)US 12233038
- Mar 30, 2037method-of-use (U-1854)US 12295927
- Mar 30, 2037method-of-use (U-1854)US 12295928
- Mar 30, 2037method-of-use (U-1854)US 12310935
FDA exclusivities (2)
- Jun 10, 2031ODE-486Orphan Drug (7y)4.6y
- Jun 10, 2029NCENew Chemical Entity (5y)2.6y
News(3)
- Charles River teams up with Ipsen to use virtual control groups in toxicology studiesCharles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma company Ipsen.fiercebiotech · 14d ago
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 3mo ago
- ‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreeNot content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…fiercebiotech · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that